Drug Companies Abandon Alzheimer’s Disease Research

Alzheimer’s Epidemic Buried Under Inaccurate Death Certificates

By Helane Shieldscshields@tds.net

The most common conventional causes of death in industrialized countries are (1.) cardiovascular disease,(2.) cancer, (3.) Alzheimer’s disease and (4.) accident (in that order). Alzheimer’s victims usually die of pneumonia, a lung condition or a cerebro-vascular condition — so Alzheimer’s victims are often declared to die of other causes.

Alzheimer's disease prevention

Best’s opening statement not only highlights the importance of Alzheimer’s as a major cause of death but also very clearly sets forth the problem error in recording the cause of death. It seems rather clear that this is obviously a major reason for the inadequate funding of research for finding the cause and a cure for Alzheimer’s disease. The number of deaths due to Alzheimer’s is grossly understated on official records.

“My great-grandfather died from “Senility.” My grandmother is way, way, way into dementia-Alzheimer’s, who could no longer speak, didn’t know any of us any longer, died of “heart failure.” My aunt, who no longer recognized anyone in her family … died of heart failure. So you’re absolutely right … it isn’t getting its dues as far as cause of death.”

Alzheimer's disease prevention

Drug companies abandon Alzheimer’s research  

Some of Australia’s leading experts on Alzheimer’s disease say an alarming number of drug companies are abandoning research into drug treatments for dementia. Despite huge advances in neuro-imaging and diagnostic techniques, there’s been little progress when it comes to drugs to fight the disease. Pharmaceutical companies now in retreat cite the huge cost of research and the failure of drug trials to date.’

Will Pharma Companies Get Out of Alzheimer’s Disease R&D?

“Clinical trial results in Alzheimer’s Disease (AD) reported over the past few weeks have been disappointing to both patients and the academic community. The failure of both bapineuzumab (Pfizer/Johnson & Johnson) and solanezumab (Eli Lilly) to improve cognitive function has shown the difficulties inherent in trying to develop drugs to treat AD.”

 Sanofi Abandons Alzheimer’s Research

“Science isn’t advanced enough to justify the costs to develop a [Alzheimer’s] drug,” says Sanofi CEO, Chris Viehbacher.”

“I think we have to do a lot more basic science work to understand what’s going on,” Viehbacher said in the interview at an industry event in San Diego. “We really, at best, partially understand the cause of the disease. It’s hard to come up with meaningful targets.”

Drug companies ‘giving up’ on Alzheimer’s treatment after series of expensive failed trials

Leading pharmaceutical companies are ‘giving up’ on a cure for Alzheimer’s after the failure of several high-profile trials. “Drug firms are scaling down the search for new Alzheimer’s treatments after spending millions on late-stage trials which have collapsed in the past five years.

“Last month Pfizer and Johnson & Johnson pulled the plug on the experimental drug bapineuzumab after the failure of two high-profile clinical trials.’

Prusiner prions Nobel Prize

Scientists who agree with Nobel Laureate Stanley Prusiner that Alzheimer’s is a prion disease:

Manuelidis, et al, 1989; Bendixen, 1996; Boller, et al, 1989, 1995; Harrison, 1991; Teixeira, 1995;  Warren, et al, 2005, Glenn Millhauser, professor of chemistry and biochemistry at UCSC.

This entry was posted in Causes, Prevention, Prion Disease, Research, Treatments and tagged . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *